Psychosis in Parkinson's disease

Primary Psychiatry

Volumn 12, Issue 7, 2005, Pages 56-62

  Marsh, Laura ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins Morris K Udall Parkinson's Disease Research Center of Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYPNOTIC SEDATIVE AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; STEROID; TOLCAPONE; ZIPRASIDONE;

BEHAVIOR DISORDER; CAREGIVER; COGNITIVE DEFECT; CONFUSION; DELIRIUM; DELUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; HALLUCINATION; HUMAN; MOOD DISORDER; PARKINSON DISEASE; PSYCHOSIS; REVIEW; RISK FACTOR; SEDATION; SLEEP DISORDER; SYMPTOMATOLOGY; VISUAL ACUITY;

EID: 22544441112     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson Disease. A community-based study. Arch Neurol. 1999;56:595-601.
2. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities associated with psychosis in patients with Parkinson's disease. Neurology. 2004;63(2):293-300.
3. Factor S, Feustel PJ, Friedman J, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003;60:1756-1761.
4. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993;43:2227-2229.
5. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology, and risk factors. Brain. 2000;123:733-745.
6. Cummings JL. Neuropsychiatric complications of drug treatment in Parkinson's disease. In: Huber SJ, Cummings JL, eds. Parkinson's Disease: Neurobehavioral Aspects. New York: Oxford University Press, 1992:314-327.
7. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:533-535.
8. Fénelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson's disease. J Neurol. 2002;249:1699-1703.
9. Peyser CE, Naimark D, Zuniga R, Jeste DV. Psychoses in Parkinson's Disease. Semin Clin Neuropsychiatry. 1998;3(1):41-50.
10. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry. 2001;70:727-733.
11. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease, Parkinsonism Related Disorders. 2004;10(4):253-254.
12. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:734-738.
13. Jimenez-Jimenez FJ, Orti-Pareja M, Gasalla T, et al. Cenesthetic hallucinations in a patient with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63(1):120.
14. Roane DM, Rogers JD, Robinson JH, Feinberg TE. Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998;10(2):194-198.
15. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson's disease. J Neural Transm. 2000;107:59-71.
16. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001;57:2078-2082.
17. Graham JM, Grunewald RA, Sagar HJ. Hallucinations in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:434-440.
18. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. 2003;19(4):433-469.
19. Roane DM, Yu M, Feinberg TE, Rogers JD. Hypersexuality after pallidal surgery for Parkinson's disease. Neuropsychiat Neuropsychol Behav Neurol. 2002;15(4):247-251.
20. Nausieda PA. Sinemet "abusers". Clin Neuropharmacol. 1985;8:318-327.
21. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12(5):375-383.
22. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA. 1971;218:1915-1920.
23. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease. A community-based prospective study. Neurology. 2001;56:730-736.
24. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol. 1997;244(1):2-8.
25. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia. 2003;41:565-574.
26. Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc. 2003;9(1):17-24.
27. Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs Aging. 1997;10(5):367-383.
28. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms. J Neural Transm. 1975;37:175-182.
29. 3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol. 1996;69:541-544.
30. Goetz CG, Pappert EJ, Blasucci LM. Intravenous levodopa in chronically-treated hallucinating Parkinson's patients: high dose pharmacological challenge does not precipitate visual hallucinations. Neurology. 1998;50:515-517.
31. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Ger Soc. 1996;44(3):296-299.
32. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53(12):1265-1268.
33. Manni R, Pacchetti C, Terzaghi M, Sartori FM, Nappi G. Hallucinations and sleep-wake cycle in PD: A 24-hour continuous polysomnographic study. Neurology. 2002;59:1979-1981.
34. Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999;14:117-121.
35. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol. 1984;15:415-418.
36. Richard IH, Papka M, Rubio A, Kurlan R. Parkinson's disease and dementia with Lewy bodies: One disease or two? Mov Disord. 2002;17(6):1161-1165.
37. McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin. 2000;18(4):865-902.
38. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124.
39. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998;51:811-814.
40. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology. 1997;48(2):376-380.
41. Burn DJ, McKeith IG. Current treatment of dementia with Lewy Bodies and Dementia associated with Parkinson's disease. Mov Disord. 2003;18(6):S72-S79.
42. Marsh L. Psychosis in Parkinson's Disease. Curr Treat Options Neurol. 2004;6(3):181-189.
43. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 2001;16(5):960-962.
44. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Related Disorders. 2002;8:193-197.
45. Marsh L. Anxiety disorders in Parkinson's disease. Int Rev Psychiatry. 2000;12(4):307-318.
46. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clinical Neurosciences. 2001;13(2):187-196.
47. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clinical Neurosciences. 1995;7(3):304-307.
48. Shulman RB. Maintenance ECT in the treatment of PD. Therapy improves psychotic symptoms, physical function. Geriatrics. 2003;58(11):43-45.
49. Andersen K, Balldin J, Gottfries CG, et al. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand. 1987;76(3):191-199.
50. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157(1):4-15.
51. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry. 1996;61:324-325.
52. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of Parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171-1195.
53. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:937-941.
54. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708-712.
55. Leroi I, Brandt J, Reich SG et al. Randomized placebo controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19(1):1-8.
56. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518.
57. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-695.
58. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353:2041.
59. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340(10):757-763.
60. Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology. 1997;48(3):658-662.
61. Friedman JH, Koller WC, Lannon MC et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology. 1997;48(4):1077- 1081.
62. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18(5):510-514.
63. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord. 2004;19(1):29-35.
64. Fernandez HH, Trieschman ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson's disease: preliminary experience. Clin Neuropharmacol. 2004;27(1):4-5.
65. Schonfeldt-Lecuona C, Connemann BJ. Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry. 2004;161(2):373-374.
66. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996;47(4):1085-1087.
67. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789-794.
68. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52:438-445.
69. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol. 2002;15:156-170.
70. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6-12.
71. Lopez D, V, Santos S. Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease. Rev Neurol 2004;39(7):661-667.
72. Connemann BJ, Schonfeldt-Lecuona C. Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry. 2004;49(1):73.
73. Grav NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol 2004;19(3):205-207.
74. Factor SA, Molho ES. Emergency department presentations of patients with Parkinson's disease. Am J Enter Med. 2000;18(2):209-215.
75. Ueda M, Hamamoto M, Nagayama H, et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology. 1999;52:777-731.